DOD Biotech PCL (BKK:DOD-F) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. DOD Biotech PCL's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.

DOD Biotech PCL's long-term debt to total assets ratio declined from Mar. 2023 (0.04) to Mar. 2024 (0.04). It may suggest that DOD Biotech PCL is progressively becoming less dependent on debt to grow their business.

DOD Biotech PCL LT-Debt-to-Total-Asset Historical Data

The historical data trend for DOD Biotech PCL's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DOD Biotech PCL LT-Debt-to-Total-Asset Chart

DOD Biotech PCL Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.05

0.04

DOD Biotech PCL Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

DOD Biotech PCL LT-Debt-to-Total-Asset Calculation

DOD Biotech PCL's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	53.285	/	1457.639
	=	0.04

DOD Biotech PCL's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	52.579	/	1415.233
	=	0.04

DOD Biotech PCL (BKK:DOD-F) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

DOD Biotech PCL LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

DOD Biotech PCL (BKK:DOD-F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-F) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

DOD:Thailand

Address

No.111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000

Website

https://www.dodbiotech.com

DOD Biotech PCL is engaged in the business of food supplements and health drinks of all kinds. The company offers Skincare products, Dietary supplements, Healthy supplements, and Own branded products. The majority of the company's revenue is derived from the supplementary business segment within Thailand. The segments of the group are Supplementary business, Manufacturing cosmetic and Network marketing, Manufacturing Extraction business, and others, of which a majority of revenue is derived from the Supplementary business segment.

DOD Biotech PCL (BKK:DOD-F) Headlines

No Headlines